Registry of biomedical companies:
[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 395 active entries
281 Kercheval Avenue
Grosse Pointe Farms, 48236
United States of America, Michigan
Phone: +1-313-263-4887
Description:
SciTech Development, Inc An oncology focused clinical-stage pharmaceutical company ST-001 nanoFenretinide: Lead Drug Candidate in Clinical Trials With innovative science and advanced nanotechnology, SciTech has developed ST-001 nanoFenretinide (ST-001), a patented new drug with clinical trials in progress for T-cell lymphoma non-Hodgkin lymphoma (T-cell NHL). The FDA has approved a second IND in March 2025 that allows for a small cell lung cancer trial to proceed. FDA has granted ST-001 Orphan Drug Designation that allows for 7 years of market exclusivity once approved. Oncology Problem: Low Drug Bioavailability Severely Limited Clinical Use Many cancer drugs, including fenretinide, have poor bioavailability due to low water solubility—resulting in sub-therapeutic dosing that fail to reach cancer cells effectively. High doses led to unacceptable toxicity and side effects. These challenges made fenretinide difficult to use for cancer treatment - until now. Solution: ST-001 nanoFenretinide with Effective Drug Delivery Platform ST-001 is a new, patented nanoparticle drug and delivery system that combines the active drug fenretinide with biocompatible phospholipids. This innovative approach enables for the rapid intravenous (IV) infusion of high-dose fenretinide, ensuring effective delivery to cancer cells and optimizes therapeutic efficacy. ► Potential use in 15+ other cancer types based on previous studies ► Overcomes bioavailability challenges and triglyceride side effects seen with prior fenretinide formulations ► Delivers a 6-fold higher formulation strength than other formulations ► Studies show safety margin of 15x compared to previous IV formulations ST-001 Clinical Trials ► Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma (ClinicalTrials.gov Identifier: NCT04234048) ► ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer (ClinicalTrials.gov Identifier: NCT06922539)
Selected Categories:
Last update of this entry: September 09, 2025
|